Physician profile
Todd S Weinstein
NPI 1760454177
$753.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.12 · 2020: $18.07 · 2021: $32.91 · 2022: $402 · 2023: $152 · 2024: $91.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $415.53 | 2022-2023 | Signia |
| Hologic Sales and Service, LLC | $47.64 | 2024 | Localizer |
| Leica Microsystems INC. | $38.75 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $29.70 | 2022 | |
| Organogenesis INC. | $29.20 | 2023 | Puraply |
| Procept Biorobotics Corporation | $27.99 | 2024 | Aquabeam System |
| Smith+Nephew, INC. | $27.22 | 2022 | |
| Heron Therapeutics, INC. | $23.66 | 2022 | |
| Genentech USA, INC. | $18.37 | 2019 | |
| Hologic INC | $18.23 | 2021 | |
| Kci USA, INC. | $18.07 | 2020 | |
| Hartmann USA, INC. | $15.73 | 2024 | Zetuvit Plus 10x10 P10 |
| Integra Lifesciences Corporation | $15.15 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Polynovo North America LLC | $13.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.